N-(3-氟丙基)丁烷-1,4-二胺 | 132151-85-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(3-氟丙基)丁烷-1,4-二胺
• 英文名称: N-3-Fluoropropylputrescine
• 英文别名: N'-(3-fluoropropyl)butane-1,4-diamine
• CAS: 132151-85-0
• 化学式: C₇H₁₇FN₂
• 分子量: 148.22
• InChiKey: JUGPUOGZSGQOPG-UHFFFAOYSA-N

物化性质

• 沸点：
  211.4±25.0 °C(Predicted)
• 密度：
  0.914±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Drug complex for treatment of metastatic prostate cancer
  申请人：Beth Israel Deaconess Medical Center

  公开号：US20030035804A1

  公开（公告）日：2003-02-20

  A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the specific cell type; a linker which is acted upon by a molecule which is present at an effective concentration in the environs of the specific cell type; and a drug or an agent to be delivered to the specific cell type. In particular, a drug complex for delivering a cytotoxic drug to prostate cancer cells, comprising a targeting carrier molecule which is selectively delivered to prostate tissue, bone or both; a peptide which is a substrate for prostate specific antigen; and a cytotoxic drug which is toxic to androgen independent prostate cancer cells.

  一种用于向靶细胞输送药物或其他制剂的药物复合物，包括一种靶向载体分子，该分子可选择性地分布到特定细胞类型或含有特定细胞类型的组织中；一种连接体，该连接体受一种分子的作用，该分子以有效浓度存在于特定细胞类型的周围环境中；以及一种要输送到特定细胞类型的药物或制剂。特别是一种向前列腺癌细胞递送细胞毒性药物的药物复合物，它包括一种靶向载体分子，可选择性地递送到前列腺组织、骨骼或两者；一种肽，它是前列腺特异性抗原的底物；以及一种细胞毒性药物，它对雄激素独立的前列腺癌细胞具有毒性。
• US6368598B1
  申请人：——

  公开号：US6368598B1

  公开（公告）日：2002-04-09
• [EN] DRUG COMPLEX FOR TREATMENT OF METASTATIC PROSTATE CANCER<br/>[FR] COMLEXE MEDICAMENTEUX POUR LE TRAITEMENT DU CANCER METASTATIQUE DE LA PROSTATE
  申请人：JCRT RADIATION ONCOLOGY SUPPOR

  公开号：WO2000001419A1

  公开（公告）日：2000-01-13

  A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the specific cell type; a linker which is acted upon by a molecule which is present at an effective concentration in the environs of the specific cell type; and a drug or an agent to be delivered to the specific cell type. In particular, a drug complex for delivering a cytotoxic drug to prostate cancer cells, comprising a targeting carrier molecule which is selectively delivered to prostate tissue, bone or both; a peptide which is a substrate for prostate specific antigen; and a cytotoxic drug which is toxic to androgen independent prostate cancer cells.